Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ferumoxytol

Novartis day

Novartis heart drug may see novel pricing plan

Swiss firm looking to risk share with payers based on clinical outcomes

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

- PMLiVE

The importance of real-world data to the pharma industry

It is a crucial time to for pharma and other stakeholders to demonstrate medicines' value

- PMLiVE

The blame game

In the 'healthcare spending crisis' it’s important to look beyond sensationalist headlines

- PMLiVE

Overcoming quantitative pricing limitations

Choosing an accurate price for a product without a therapeutic equivalent can feel like a lead in the dark

- PMLiVE

Patient survey finds pharma falls short on drug pricing

The industry is coming under increasing attack from all sides as price tags rise

ABPI London offices

UK pharma rebate payment doubles in one year

First quarter repayment £138m higher than this time last year

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

- PMLiVE

US lawmakers pass new bill to speed up drug reviews

FDA will also need to take the views of patients into greater consideration under new plans

- PMLiVE

George Freeman re-appointed as UK life science minister

Industry welcomes his continuation in this pharma-focused role

- PMLiVE

Is a UK market access shake-up on the cards?

Former coalition government health minister Paul Burstow tells PMLiVE that NICE, QALY and broader issues of market access in England are all being put under review

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links